Immuron Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
1,044.10
1,123.70
1,001.10
1,396.20
1,842.90
Cost of Goods Sold (COGS) incl. D&A
1,572.80
891.30
1,294.60
1,288.00
1,808.00
Gross Income
528.60
232.40
293.50
108.20
34.90
SG&A Expense
2,182.30
4,445.00
7,750.60
8,126.80
4,713.70
EBIT
2,710.90
4,248.00
-
8,155.10
4,842.50
Non Operating Income/Expense
2.50
34.90
203.90
208.30
0.00
Interest Expense
588.60
-
341.60
24.50
18.90
Pretax Income
3,208.70
4,170.40
8,581.60
8,379.50
4,860.10
Income Tax
664.20
722.50
2,982.60
1,575.30
1,849.10
Consolidated Net Income
2,544.60
3,448.00
5,599.00
6,804.20
3,010.90
Net Income
2,544.60
3,448.00
5,599.00
6,804.20
3,010.90
Net Income After Extraordinaries
2,544.60
3,448.00
5,599.00
6,804.20
3,010.90
Net Income Available to Common
2,544.60
3,448.00
5,599.00
6,804.20
3,010.90
EPS (Basic)
0.06
0.05
0.07
0.06
0.02
Basic Shares Outstanding
42,223.80
75,578.30
76,436.00
105,866.10
133,660.60
EPS (Diluted)
0.06
0.05
0.07
0.06
0.02
Diluted Shares Outstanding
42,223.80
75,578.30
76,436.00
105,866.10
133,660.60
EBITDA
2,026.30
4,244.30
8,044.40
8,150.10
4,837.40
Other Operating Expense
-
35.30
4.20
136.50
163.60
Non-Operating Interest Income
88.30
112.40
12.20
8.40
1.20

About Immuron

View Profile
Address
62 Lygon Street
Carlton Victoria (VIC) 3053
Australia
Employees -
Website http://www.immuron.com
Updated 07/08/2019
Immuron Ltd. engages in the research and development of oral immunotherapy treatments using dairy-derived antibody products for humans. It operates through the following segments: Research and Development; HyperImmune Products; and Corporate. The Research and Development segment involves the research and development projects performed in Australia and Israel.